Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study - PubMed (original) (raw)

Clinical Trial

doi: 10.1186/1471-2407-6-5.

Sabino De Placido, Rosalbino Biamonte, Giovanni Scambia, Giovanni Di Vagno, Giuseppe Colucci, Antonio Febbraro, Marco Marinaccio, Alessandra Vernaglia Lombardi, Luigi Manzione, Giacomo Cartenì, Mario Nardi, Saverio Danese, Maria Rosaria Valerio, Andrea de Matteis, Bruno Massidda, Giampietro Gasparini, Massimo Di Maio, Carmela Pisano, Francesco Perrone

Affiliations

Clinical Trial

Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study

Sandro Pignata et al. BMC Cancer. 2006.

Abstract

Background: Carboplatin/paclitaxel is the chemotherapy of choice for advanced ovarian cancer, both in first line and in platinum-sensitive recurrence. Although a significant proportion of patients have some neurotoxicity during treatment, the long-term outcome of chemotherapy-induced neuropathy has been scantly studied. We retrospectively assessed the prevalence of residual neuropathy in a cohort of patients in clinical remission after first-line carboplatin/paclitaxel for advanced ovarian cancer.

Methods: 120 patients have been included in this study (101 participating in a multicentre phase III trial evaluating the efficacy of consolidation treatment with topotecan, and 19 treated at the National Cancer Institute of Naples after the end of the trial). All patients received carboplatin (AUC 5) plus paclitaxel (175 mg/m2) every 3 weeks for 6 cycles, completing treatment between 1998 and 2003. Data were collected between May and September 2004. Residual sensory and motor neurotoxicity were coded according to the National Cancer Institute--Common Toxicity Criteria.

Results: 55 patients (46%) did not experience any grade of neurological toxicity during chemotherapy and of these none had signs of neuropathy during follow-up. The other 65 patients (54%) had chemotherapy-induced neurotoxicity during treatment and follow-up data are available for 60 of them. Fourteen out of 60 patients (23%) referred residual neuropathy at the most recent follow-up visit, after a median follow up of 18 months (range, 7-58 months): 12 patients had grade 1 and 2 patients grade 2 peripheral sensory neuropathy; 3 patients also had grade 1 motor neuropathy. The remaining 46/60 patients (77%) had no residual neuropathy at the moment of interview: recovery from neurotoxicity had occurred in the first 2 months after the end of chemotherapy in 22 (37%), between 2 and 6 months in 15 (25%), or after more than 6 months in 9 patients (15%). Considering all 120 treated patients, there was a 15% probability of persistent neurological toxicity 6 months after the end of chemotherapy.

Conclusion: A significant proportion of patients with advanced ovarian cancer treated with first-line carboplatin/paclitaxel suffer long-term residual neuropathy. This issue should be carefully taken into account before considering re-treatment with the same agents in sensitive recurrent disease.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Kaplan-Meyer curve of time to resolution of neurological toxicity in patients with epithelial ovarian carcinoma treated with the combination of carboplatin and paclitaxel (dotted lines represent 95% confidence interval).

Figure 2

Figure 2

Duration of residual neuro-toxicity according to age category.

Figure 3

Figure 3

Kaplan-Meyer curve of time to resolution of neurological toxicity according to grade of toxicity reported during chemotherapy.

Similar articles

Cited by

References

    1. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J, Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320–1329. - PubMed
    1. Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, de Swart CA, Hirsch FR, Lund B, van Houwelingen HC. Exploratory phase III study of cisplatin and paclitaxel versus carboplatin and paclitaxel in advanced ovarian cancer. J Clin Oncol. 2000;18:3084–3092. - PubMed
    1. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R, Gynecologic Oncology Group Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:2460–2465. doi: 10.1200/JCO.2003.07.013. - DOI - PubMed
    1. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Trope C, ICON and AGO Collaborators Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4 / AGO-OVAR-2.2 trial. Lancet. 2003;361:2099–2106. doi: 10.1016/S0140-6736(03)13718-X. - DOI - PubMed
    1. National Cancer Institute – Cancer Therapy Evaluation Program. Common Toxicity Criteria. Version 2.0 April 30, 1999 http://ctep.info.nih.gov

Publication types

MeSH terms

Substances

LinkOut - more resources